XML 45 R29.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Current Accrued Liabilities and Accrued Research and Development (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2016
Disclosure Component Of Current Accrued Liabilities And Accrued Research And Development [Abstract] |
Component of Current Accrued Liabilities and Accrued Research and Development | Current accrued liabilities and accrued research and development consist of the following (in thousands):
| December 31, |
| 2016 |  |  | 2015 |
Payroll and related expenses | $ | 3,753 |  |  | $ | 5,866 |
Legal expenses |  | 275 |  |  |  | 202 |
Litigation settlements accrual (Note 7) |  | 4,975 |  |  |  | - |
Third party research expenses |  | 2,784 |  |  |  | 5,241 |
Third party development expenses |  | 2,002 |  |  |  | 2,072 |
Return of unused development funding to AstraZeneca (Note 9) |  | - |  |  |  | 7,345 |
Other accrued liabilities |  | 2,451 |  |  |  | 1,972 |
Total | $ | 16,240 |  |  | $ | 22,698 |

X
- Definition Disclosure component of current accrued liabilities and accrued research and development. + References No definition available. + Details
Name: | dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract
Namespace Prefix: | dvax_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Schedule of accrued liabilities and accrued research and development. + References No definition available. + Details
Name: | dvax_ScheduleOfAccruedLiabilitiesAndAccruedResearchAndDevelopmentTableTextBlock
Namespace Prefix: | dvax_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration